Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

Compare

684 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MIRM Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Mirum

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$71.43

▲(35.46%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $71.43 with a high forecast of $77.00 and a low forecast of $56.00. The average price target represents a 35.46% change from the last price of $52.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","78":"$78","36.75":"$36.8","50.5":"$50.5","64.25":"$64.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$77.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,36.75,50.5,64.25,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.39,50.59076923076923,52.791538461538465,54.99230769230769,57.19307692307692,59.393846153846155,61.59461538461538,63.79538461538461,65.99615384615385,68.19692307692307,70.39769230769231,72.59846153846154,74.79923076923077,{"y":77,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.39,50.16230769230769,51.934615384615384,53.706923076923076,55.479230769230774,57.251538461538466,59.02384615384616,60.79615384615385,62.56846153846154,64.34076923076924,66.11307692307693,67.88538461538462,69.65769230769232,{"y":71.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.39,48.97538461538461,49.56076923076923,50.146153846153844,50.73153846153846,51.316923076923075,51.902307692307694,52.487692307692306,53.073076923076925,53.65846153846154,54.24384615384616,54.82923076923077,55.41461538461539,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$77.00

Average Price Target$71.43

Lowest Price Target$56.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$56

Hold

6.20%

Upside

Reiterated

07/10/25

Mirum Pharmaceuticals demonstrates strong revenue growth and positive momentum from recent earnings, reflected in a high earnings call score. However, financial performance and valuation are areas of concern due to profitability challenges and negative cash flows. Technical analysis suggests bullish momentum, but potential overbought conditions may limit near-term upside.

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$68→$76

Buy

44.13%

Upside

Reiterated

07/11/25

Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISIMirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$73

Buy

38.44%

Upside

Initiated

05/19/25

Mirum Pharmaceuticals assumed with a Buy at H.C. WainwrightMirum Pharmaceuticals assumed with a Buy at H.C. Wainwright

Ryan DeschnerRaymond James

Raymond James

$77

Buy

46.03%

Upside

Reiterated

05/13/25

Mirum Pharmaceuticals (MIRM) Receives a Buy from Raymond James

David LebowitzCiti

Citi

$68→$72

Buy

36.54%

Upside

Reiterated

05/12/25

Analysts Conflicted on These Healthcare Names: Regulus (NASDAQ: RGLS), Mirum Pharmaceuticals (NASDAQ: MIRM) and Kymera Therapeutics (NASDAQ: KYMR)

Jonathan WollebenCitizens JMP

Citizens JMP

$74→$76

Buy

44.13%

Upside

Reiterated

05/09/25

Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMPMirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP

Michael UlzMorgan Stanley

Morgan Stanley

$65→$70

Buy

32.75%

Upside

Reiterated

05/09/25

Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating

Mani ForooharLeerink Partners

Leerink Partners

$55→$56

Buy

6.20%

Upside

Reiterated

05/07/25

Analysts Are Bullish on Top Healthcare Stocks: Bio-Techne (TECH), Mirum Pharmaceuticals (MIRM)

Jessica FyeJ.P. Morgan

J.P. Morgan

$53

Buy

0.51%

Upside

Reiterated

04/04/25

J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Brian SkorneyRobert W. Baird

Robert W. Baird

$50→$55

Buy

4.30%

Upside

Reiterated

02/27/25

Mirum Pharmaceuticals price target raised to $55 from $50 at BairdMirum Pharmaceuticals price target raised to $55 from $50 at Baird

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$66→$70

Buy

32.75%

Upside

Reiterated

11/12/24

Mirum Pharamceuticals (MIRM) PT Raised to $70 at StifelStifel analyst Dae Gon Ha raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $70.00 (from $66.00) while maintaining a Buy rating.

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$45→$60

Buy

13.79%

Upside

Reiterated

08/07/24

Mirum Pharmaceuticals (MIRM) Receives a Buy from Cantor Fitzgerald

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$56

Hold

6.20%

Upside

Reiterated

07/10/25

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$68→$76

Buy

44.13%

Upside

Reiterated

07/11/25

Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISIMirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI

Swayampakula RamakanthH.C. Wainwright

H.C. Wainwright

$73

Buy

38.44%

Upside

Initiated

05/19/25

Mirum Pharmaceuticals assumed with a Buy at H.C. WainwrightMirum Pharmaceuticals assumed with a Buy at H.C. Wainwright

Ryan DeschnerRaymond James

Raymond James

$77

Buy

46.03%

Upside

Reiterated

05/13/25

Mirum Pharmaceuticals (MIRM) Receives a Buy from Raymond James

David LebowitzCiti

Citi

$68→$72

Buy

36.54%

Upside

Reiterated

05/12/25

Analysts Conflicted on These Healthcare Names: Regulus (NASDAQ: RGLS), Mirum Pharmaceuticals (NASDAQ: MIRM) and Kymera Therapeutics (NASDAQ: KYMR)

Jonathan WollebenCitizens JMP

Citizens JMP

$74→$76

Buy

44.13%

Upside

Reiterated

05/09/25

Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMPMirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP

Michael UlzMorgan Stanley

Morgan Stanley

$65→$70

Buy

32.75%

Upside

Reiterated

05/09/25

Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating

Mani ForooharLeerink Partners

Leerink Partners

$55→$56

Buy

6.20%

Upside

Reiterated

05/07/25

Analysts Are Bullish on Top Healthcare Stocks: Bio-Techne (TECH), Mirum Pharmaceuticals (MIRM)

Jessica FyeJ.P. Morgan

J.P. Morgan

$53

Buy

0.51%

Upside

Reiterated

04/04/25

J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Brian SkorneyRobert W. Baird

Robert W. Baird

$50→$55

Buy

4.30%

Upside

Reiterated

02/27/25

Mirum Pharmaceuticals price target raised to $55 from $50 at BairdMirum Pharmaceuticals price target raised to $55 from $50 at Baird

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$66→$70

Buy

32.75%

Upside

Reiterated

11/12/24

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$45→$60

Buy

13.79%

Upside

Reiterated

08/07/24

Mirum Pharmaceuticals (MIRM) Receives a Buy from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

1 Month

xxx

Success Rate

16/33 ratings generated profit

Average Return

+2.64%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.48% of your transactions generating a profit, with an average return of +2.64% per trade.

3 Months

xxx

Success Rate

21/33 ratings generated profit

Average Return

+7.19%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +7.19% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

16/16 ratings generated profit

Average Return

+38.25%

reiterated a buy rating 2 months ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +38.25% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+76.89%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +76.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MIRM has received 8 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 71.43.

Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.33 with a range of -$0.50 to -$0.21. The previous quarter’s EPS was -$0.30. MIRM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.07% of the time in the same period. In the last calendar year MIRM has Preformed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $107.92M with a range of $104.30M to $110.60M. The previous quarter’s sales results were $111.58M. MIRM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year MIRM has Preformed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?

Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 71.43.

What is MIRM’s upside potential, based on the analysts’ average price target?

Mirum Pharmaceuticals Inc has 35.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MIRM a Buy, Sell or Hold?

Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mirum Pharmaceuticals Inc’s price target?

The average price target for Mirum Pharmaceuticals Inc is 71.43. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $77.00 ,the lowest forecast is $56.00. The average price target represents 35.46% Increase from the current price of $52.73.

What do analysts say about Mirum Pharmaceuticals Inc?

Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of MIRM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

MIRM Analyst Ratings

MIRM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mirum Pharmaceuticals

MIRM Analyst Recommendation Trends

MIRM Financial Forecast

MIRM Earnings Forecast

MIRM Sales Forecast

MIRM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts